The Gelesis team includes proven entrepreneurs and leaders in obesity & metabolism, healthcare and commercialization
Dr. Chiquette joins Gelesis with over 15 years’ experience in Medical Affairs within the pharmaceutical, biotechnology, and medical device industries.
Dr. Chiquette was involved in developing medical strategies for first-in-class launches like orlistat, GLP-1 agonist, amylin analog, endobarrier device, and metreleptin at Hoffman La Roche, Amylin Pharmaceuticals, Aegerion and GI Dynamics. In her leadership roles throughout the years, Dr. Chiquette built strong expertise in regulatory affairs for pharmaceuticals, biologics, and devices in both United States and Europe. Prior to launching her career in industry, Dr. Chiquette completed her pharmacy degree at Laval University in Quebec, a Pharm.D. At University of Texas Health Science Center at San Antonio, followed by a post-doctorate fellowship in Epidemiology. Dr. Chiquette served as Deputy Director for the San Antonio Evidence-Based Practice Center program for the US government Agency for Healthcare Research and Quality and authored several meta-analyses. In that capacity, Dr. Chiquette led the supportive evidence report for the National Institute of Health Obesity Guidelines in 1998 and co-authored the associated publications. Since then, her career, publications and interest has been focused on therapeutic options for cardiometabolic diseases.
See our scientific advisors